The Metal-Based Markers segment dominated the market with a revenue share of 48.6% in 2025, driven by their high radiopacity, stability, and compatibility with multiple imaging modalities such as CT, MRI, and X-ray systems. Metal fiducials provide superior visibility during image-guided radiotherapy (IGRT), ensuring precise tumor targeting. https://www.databridgemarketresearch.com/reports/global-fiducial-markers-market